Direct Compression Tablet Manufacturing with Nebivolol Hydrochloride

Commercial immediate-release tablet cores containing nebivolol hydrochloride are frequently designed within a total core mass of 150 mg to 250 mg, with API loading calculated against the nominal label claim as 1.0% w/w for a 2.5 mg strength and 10.0% w/w for a 20 mg strength when the core mass is fixed at 200 mg. A production-scale blend for low-dose beta-blocker tablets cannot rely on direct addition of the API to the main diluent because segregation and electrostatic adhesion to blender surfaces create content uniformity drift; instead, the API is first passed through a 500 µm stainless steel sieve, preblended 1:1 with microcrystalline cellulose or lactose monohydrate in a bin blender at 15 rpm for 5 min, then combined with the remaining diluent and croscarmellose sodium as disintegrant. Colloidal silicon dioxide is added at 0.2%–0.5% w/w to improve flow, and magnesium stearate at 0.5%–1.5% w/w is introduced only after the final preblend has reached acceptable blend uniformity; lubricant contact time is kept below 5 min under high shear because excessive hydrophobic surface coverage can slow dissolution of the low-solubility API. Compression is executed on a 36-station rotary tablet press under force-controlled feedback, with individual tablet hardness maintained between 40 N and 80 N and friability not exceeding 1.0% under USP <1216>. In-process sampling follows 21 CFR 211.110, with weight, hardness, thickness, and disintegration measured at defined intervals; blend content uniformity is checked at start, middle, and end sampling ports because low-dose direct compression blends can exhibit top-to-bottom API segregation after extended bin transfer. Residual moisture in the blend is held below 3.0% because wet granules are not formed in this route and higher moisture can reduce flow and alter the compaction properties of microcrystalline cellulose. The film-coating step applies an aqueous hypromellose-based dispersion to a 2.0%–3.0% weight gain, mainly to reduce dusting and mask the slightly bitter API. Compliance for the terminal product includes USP <905> Uniformity of Dosage Units with an acceptance value ≤ 15.0, Ph. Eur. 2.9.40 Content Uniformity, USP <711> dissolution using a product-specified aqueous surfactant medium validated per ICH Q2(R1), and elemental impurity control under ICH Q3D. The terminal finished product type is immediate-release film-coated tablets; this route is not appropriate for modified-release dosage forms without separate rate-controlling matrix development.

In low-dose capsule filling, geometric dilution is the controlling unit operation because direct mixing of an API present at less than 5.0% w/w into a 150–200 mg fill mass creates sampling bias, segregation, and high rejection risk at automated capsule machines. A 2.5 mg nebivolol hydrochloride dose in a 150 mg fill mass corresponds to 1.67% w/w; a 10 mg dose corresponds to 6.67% w/w, which remains low enough to require staged dilution. The process starts with a 1:10 preblend of API and lactose monohydrate or pregelatinized starch, passed through a 710 µm sieve, then diluted to 1:25 and 1:50 before final mixing in a tumble blender at 25 rpm for 15–20 min. Automated capsule filling is performed on a tamping-pin machine with dosing chamber height and tamping force set to avoid powder plugging; fill weight is checked every 15 min and at start, middle, and end of the batch. Capsule shells are normally hard gelatin or HPMC size 3 or 4, and filling is conducted in a controlled environment to prevent brittleness or softening. Compliance includes USP <905> Uniformity of Dosage Units, USP <711> dissolution, Ph. Eur. 2.9.40 Content Uniformity, and 21 CFR 211.110 in-process sampling. Magnesium stearate, if used, is limited to 0.5%–1.0% w/w and added after final dilution because early addition can coat API particles and slow dissolution. The terminal finished product type is hard capsules for dose titration or clinical supply; the route is incompatible with enteric-coated bead delivery unless a separate multi-particulate platform is developed.

For single-dose sachet granules intended for sprinkling on soft food or reconstitution immediately before oral administration, the granulation endpoint is selected to balance particle strength against dispersibility: granules must survive packaging and transport with minimal attrition, yet disaggregate rapidly in the mouth or in water. Nebivolol hydrochloride is incorporated at a final granule fraction of 0.25%–2.5% w/w, with a 2.5 mg label claim typically loaded into a 500 mg granule mass, corresponding to 0.5% w/w. The manufacturing process begins by dispersing the API in an aqueous binding solution containing povidone K30 and, where warranted by low wettability, 0.1% polysorbate 80; the dispersion is sprayed onto a lactose-mannitol or microcrystalline cellulose bed in a top-spray fluid-bed granulator at atomization pressure 1.5–2.0 bar, inlet air temperature 50–60°C, and product temperature 30–38°C. Spray rate is not a fixed value; it is adjusted to maintain granule moisture below the dew-point limit of the filter bag, because overdampening creates uncontrolled agglomerates. Drying continues until residual moisture by loss on drying reaches 1.5%–2.5%; granules are then milled through an oscillating mill with a 1.0 mm screen, and the fraction between 150 µm and 800 µm is retained for sachet filling. Fine particles below 150 µm are either regranulated or removed to reduce dusting during stick-pack filling. The final granules are filled under relative humidity not exceeding 40% to avoid caking and are sealed into foil-lined sachets. Compliance includes Ph. Eur. 2.9.12 Sieve Test, USP <786> Particle Size Distribution, Ph. Eur. 2.9.40 for content uniformity of single-dose preparations, USP <711> for dissolution where the granule is intended for immediate release, and ICH Q3D elemental impurity limits. The terminal finished product type is oral granules in single-dose sachets; published commercial examples of nebivolol sachet products are limited, so the described line is a development-scale or compounding-scale configuration rather than a replicated reference product.

Why Does Low-Dose Oral Liquid Compounding Require pH Adjustment Rather Than Simple Water Reconstitution?

Compounding a uniform oral liquid from nebivolol hydrochloride is not a simple water-reconstitution step because the drug substance has pH-dependent wettability and may aggregate or settle when dispersed into an unmodified aqueous vehicle. In extemporaneous oral liquid compounding, the API is generally incorporated at a working concentration of 0.1 mg/mL to 2.0 mg/mL, allowing dose titration from 1.25 mg to 10 mg using volumetric administration. The process begins by wetting the API with glycerin or propylene glycol in a mortar, then levigating the wetted mass into a suspending vehicle based on microcrystalline cellulose and carboxymethylcellulose sodium; pH is adjusted with citrate buffer to maintain the acidic range of approximately 4.0–4.5, because higher pH reduces wetting and promotes particle aggregation. The preparation is transferred to amber polyethylene terephthalate bottles and labeled with a beyond-use date determined by stability data; where stability data are absent, non-conserved aqueous preparations are assigned conservative beyond-use limits under USP <795>. Compliance references include USP <795> Pharmaceutical Compounding—Nonsterile Preparations, USP <1163> Quality Assurance in Pharmaceutical Compounding, and USP <51> Antimicrobial Effectiveness where a preserved multi-dose vehicle is used. The terminal finished product type is an extemporaneously compounded oral suspension; published stability data for nebivolol oral liquid are limited, so batch-specific beyond-use assignment and appearance monitoring are required.

When Aseptic Filtration Encounters Poorly Soluble Hydrochloride APIs: Injectable Feasibility Screening

Because published data for a commercial nebivolol injectable presentation are limited, injectable formulation screening is treated as a feasibility exercise rather than a replicated commercial process. Nebivolol hydrochloride is a lipophilic molecule with pH-dependent aqueous solubility; at neutral pH the free-base form is poorly wettable, so parenteral development work is forced toward acidic buffered systems, co-solvent systems, or cyclodextrin complexation rather than simple aqueous dissolution. In preformulation screening, drug substance concentrations of 0.05 mg/mL to 0.5 mg/mL are evaluated for intravenous infusion, and cyclodextrin-based systems may require molar ratios of API to carrier between 1:5 and 1:20; however, published data for this specific configuration are limited, and these values are screening ranges rather than compendial limits. The manufacturing process under aseptic conditions begins by dissolving the hydrochloride salt in pH 3.0–4.5 citrate or acetate buffer under low-shear mixing, adding a stabilizer or cyclodextrin if required, and adjusting pH to the target range with dilute hydrochloric acid or sodium hydroxide. The bulk solution is then filtered through a 0.22 µm PVDF or PES membrane; filter compatibility studies are required because lipophilic APIs can adsorb to membrane surfaces and reduce potency after filtration. Aseptic filling is performed in a Grade A unidirectional airflow zone with Grade B background, using Type I borosilicate glass vials and elastomeric closures; terminal sterilization is not assumed because thermal exposure may degrade the molecule unless stability studies demonstrate otherwise. For lyophilized screening formulations, the filtered solution is filled into vials, partially stoppered, frozen on lyophilizer shelves, and primary dried under vacuum; cake collapse occurs if the formulation glass transition temperature is exceeded. Compliance includes USP <1> Injections, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins, 21 CFR 210/211, and ICH Q3D. The terminal finished product type is a sterile injectable solution or lyophilized powder for reconstitution; the route is constrained by low aqueous solubility, filter adsorption risk, and the absence of a robust commercial regulatory precedent.